{"id":37157,"date":"2021-02-16T16:33:10","date_gmt":"2021-02-16T15:33:10","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=37157"},"modified":"2022-04-09T03:18:08","modified_gmt":"2022-04-09T01:18:08","slug":"12-february-2021-dermapharm-holding-se-expects-the-cooperation-with-biontech-se-in-vaccine-production-to-make-a-high-double-digit-million-e-contribution-to-sales-in-2021","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/en\/12-february-2021-dermapharm-holding-se-expects-the-cooperation-with-biontech-se-in-vaccine-production-to-make-a-high-double-digit-million-e-contribution-to-sales-in-2021\/","title":{"rendered":"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221; _builder_version=&#8221;4.16&#8243; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; padding_mobile=&#8221;off&#8221; column_padding_mobile=&#8221;on&#8221; admin_label=&#8221;Zeile&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; custom_padding=&#8221;||0px|&#8221; make_fullwidth=&#8221;off&#8221; use_custom_width=&#8221;off&#8221; width_unit=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;Schaltfl\u00e4che %22zur\u00fcck zum Archiv%22&#8243; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<style>\n.zur\u00fcckbutton:before {<br \/>    display: inline-block;<br \/>    font-family: \"ETmodules\";<br \/>    content: \"4a\";<br \/>    color: #00225f;<br \/>    margin-right: 7px;<br \/>}<br \/>.zur\u00fcckbutton:hover:before {<br \/>    display: inline-block;<br \/>    font-family: \"ETmodules\";<br \/>    content: \"4a\";<br \/>    color: #d85710;<br \/>    margin-right: 7px;<br \/>}<br \/><\/style>\n<h1 style=\"text-align: justify;\">Ad hoc news<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><br \/>\n[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png&#8221; align=&#8221;right&#8221; align_tablet=&#8221;center&#8221; align_phone=&#8221;&#8221; align_last_edited=&#8221;on|desktop&#8221; admin_label=&#8221;Logo&#8221; _builder_version=&#8221;4.16&#8243; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221; animation=&#8221;off&#8221; sticky=&#8221;off&#8221; always_center_on_mobile=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8221;row&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1><strong><em>Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 <\/em><\/strong><\/h1>\n<p>Gr\u00fcnwald, February 12, 2021 &#8211; Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) expects the cooperation with BioNTech SE, Mainz, in the production of the Covid-19 vaccine Comirnaty\u00ae to contribute a high double-digit million \u20ac amount to the consolidated sales of the Dermapharm Group in the full year 2021. This is the result of a current plan for vaccine production approved today by the Management Board of Dermapharm Holding SE. Among other things, it includes the establishment of additional production capacities at the Reinbek site, which are scheduled to go into operation in May 2021. <\/p>\n<p><strong>Contacts<\/strong><br \/>\nInvestor Relations &amp;<br \/>\nCorporate Communications<br \/>\nBritta Hamberger<br \/>\nPhone: +49 (0)89 \u2013 64186-233<br \/>\nFax: +49 (0)89 \u2013 64186-165<br \/>\nE-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com<\/a><\/p>\n<p><strong>cometis AG <\/strong><br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nE-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com <\/a>[\/et_pb_text][et_pb_text admin_label=&#8221;Schaltfl\u00e4che %22Beitrag als PDF%22&#8243; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2021\/02\/EN_20210212_ad-hoc_Biontech_FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Read as PDF<\/a><\/div>\n<style> .leseprobe-archiv {color: #00225f !important; border-color: #00225f; position: relative; padding: 0.3em 1em; border: 1px solid; -webkit-border-radius: 3px; -moz-border-radius: 3px; border-radius: 3px; -webkit-transition: all 0.2s; -moz-transition: all 0.2s; transition: all 0.2s; padding:10px; width: 19%; text-align: center; margin-right: 10px; float:left;} .leseprobe-archiv:hover {background-color: #eee; border-color: #ffffff; cursor: pointer;}<\/style>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ad hoc news to the archive Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 Gr\u00fcnwald, February 12, 2021 &#8211; Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) expects the cooperation with BioNTech SE, Mainz, in the production of the Covid-19 [&hellip;]<\/p>\n","protected":false},"author":24813,"featured_media":89714,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[325,448,5],"tags":[483],"class_list":["post-37157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-ad-hoc-news","category-news-en","category-uncategorized","tag-483"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 - cometis AG<\/title>\n<meta name=\"description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-16T15:33:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-09T01:18:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\"},\"headline\":\"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021\",\"datePublished\":\"2021-02-16T15:33:10+00:00\",\"dateModified\":\"2022-04-09T01:18:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/\"},\"wordCount\":538,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"keywords\":[\"2021\"],\"articleSection\":[\"Dermapharm Ad-Hoc News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/\",\"url\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/\",\"name\":\"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"datePublished\":\"2021-02-16T15:33:10+00:00\",\"dateModified\":\"2022-04-09T01:18:08+00:00\",\"description\":\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg\",\"caption\":\"icon_newsroom\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 - cometis AG","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 - cometis AG","og_description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","og_url":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/","og_site_name":"cometis AG","article_published_time":"2021-02-16T15:33:10+00:00","article_modified_time":"2022-04-09T01:18:08+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6"},"headline":"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021","datePublished":"2021-02-16T15:33:10+00:00","dateModified":"2022-04-09T01:18:08+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/"},"wordCount":538,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2021"],"articleSection":["Dermapharm Ad-Hoc News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/","url":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/","name":"12 February 2021 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million \u20ac contribution to sales in 2021 - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2021-02-16T15:33:10+00:00","dateModified":"2022-04-09T01:18:08+00:00","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/12-februar-2021-dermapharm-holding-se-erwartet-aus-der-kooperation-mit-der-biontech-se-bei-der-impfstoff-produktion-einen-umsatzbeitrag-fuer-2021-im-hohen-zweistelligen-mio-e-bereich\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","caption":"icon_newsroom"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/37157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=37157"}],"version-history":[{"count":3,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/37157\/revisions"}],"predecessor-version":[{"id":62736,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/37157\/revisions\/62736"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media\/89714"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=37157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=37157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=37157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}